Earnings ·
Relay Therapeutics reports Q3 net loss of $81.7M and holds $849M in cash
RLAYRelay Therapeutics, Inc.
Relay Therapeutics reported a third-quarter 2026 net loss of $81.7 million, or $0.37 per share, compared to a $74.1 million loss in the prior-year period. Research and development expenses rose to $77.1 million from $68.3 million, driven by increased clinical trial costs and non-recurring lease termination charges. The company ended the quarter with approximately $849 million in cash, cash equivalents, and investments, projecting that current funds will support operations into 2029. Corporate updates include an estimated mid-2027 completion of enrollment for the Phase 3 ReDiscover-2 breast cancer trial and a new TIE2 inhibitor program. Relay Therapeutics is a clinical-stage precision medicine company developing therapies for cancer and genetic diseases.